Previous Close | €27.51 |
AI Value | €94.90 |
Upside potential | +245% |
Bayer AG is a global life sciences company with core operations in pharmaceuticals, consumer health, and crop science. The company holds a strong market position, particularly in agriculture (via its Crop Science division) and prescription pharmaceuticals (notably in cardiovascular and women's health). Bayer's acquisition of Monsanto in 2018 significantly expanded its agricultural biotechnology portfolio, though it also introduced legal and reputational challenges. The company differentiates itself through its integrated healthcare and agriculture solutions, R&D capabilities, and strong brand recognition in key markets like Europe and North America.
Leading R&D pipeline in pharmaceuticals (particularly oncology and cardiology); strong IP portfolio in crop traits and agrochemicals; investments in digital agriculture platforms
Bayer offers exposure to structurally growing healthcare and agriculture markets with technological leadership positions, but investment appeal is currently constrained by litigation overhangs and integration challenges. The stock may appeal to value-oriented investors if litigation risks subside and pipeline assets deliver, but requires careful monitoring of legal developments and R&D execution. Near-term volatility is likely to persist.
Bayer Annual Report 2022, Bloomberg Intelligence, company investor presentations, European Medicines Agency disclosures
Historical valuation data is not available at this time.